Soteria

Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Francisco, California.

https://www.soteriabiotherapeutics.com/

Team Member
more about
Therese Liechtenstein
Latest News Entry
2021/05/17
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures

Proceeds to fund early pipeline of novel switchable bispecific T-cell engagers to treat solid tumor cancers

Company's proprietary T-LITE platform based on small molecule-dependent activation of T-cell engagers, enabling potentially safer and more efficacious tumor targeted therapy

Seasoned leadership to steer company's growth and pipeline development

2020/11/12
Soteria Biotherapeutics Announces Scientific Advisory Board

Soteria Biotherapeutics, Inc. today announced the formation of a scientific advisory board to help guide the company's early stage research and development.

all portfolio news